Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
CTC testing, seen as vital for metastatic cancer, is poised to become routine in five years, backed by global experts and 90% support.
A major international expert consensus published in the European Journal of Cancer affirms the clinical value of circulating tumor cells (CTCs) in cancer care, stating they provide unique insights not available through ctDNA and predicting CTC testing will become routine in clinical practice within five years, especially for metastatic cancer.
The consensus, developed by 32 global oncologists, found 90% support for CTC integration into oncology, with 40% identifying Cellbxhealth’s Parsortix® platform as the most promising technology.
The company, which reported a cash runway into early 2026, is seeking to raise £6 million through a retail and institutional offering, with an announcement expected by early December.
The peer-reviewed study is available online.
Las pruebas de CTC, consideradas vitales para el cáncer metastásico, están a punto de convertirse en rutina en cinco años, respaldadas por expertos globales y con el apoyo del 90%.